Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.
The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.
Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -0.06 Increased by +45.45% | -0.12 Increased by +50.00% |
| Feb 13, 24 | -0.11 Increased by +26.67% | -0.10 Decreased by -10.00% |
| Nov 14, 23 | -0.10 Increased by +9.09% | -0.12 Increased by +16.67% |
| Sep 20, 23 | -0.10 Increased by 0.00% | -0.11 Increased by +9.09% |
| May 11, 23 | -0.11 Decreased by -37.50% | -0.16 Increased by +31.25% |
| Feb 10, 23 | -0.15 Decreased by -200.00% | -0.11 Decreased by -36.36% |
| Nov 10, 22 | -0.11 Decreased by -57.14% | -0.10 Decreased by -10.00% |
| Sep 9, 22 | -0.10 Increased by +93.71% | -0.07 Decreased by -42.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | N/A Decreased by N/A% | -1.65 M Increased by +39.47% | - - |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.72 M Increased by +29.25% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -2.48 M Increased by +5.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -2.50 M Decreased by -7.66% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -2.73 M Decreased by -45.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.84 M Decreased by -257.95% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -2.61 M Decreased by -68.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -2.32 M Increased by +92.04% | Decreased by N/A% Decreased by N/A% |